Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601290 | 1.00 | FNTA (0.32) | FNTAFNTBMAP3K14NR1H2CSNK2A2 | |
| SCHEMBL23576987 | 0.91 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL23601039 | 0.91 | PTGES (0.36) | FNTAFNTBMAP3K14CSNK2A2CSNK2B | |
| SCHEMBL23601040 | 0.89 | FNTA (0.34) | FNTAFNTBMAP3K14CSNK2A2CSNK2B | |
| SCHEMBL23576764 | 0.89 | FNTA (0.31) | FNTAFNTBMAP3K14NR1H2 | |
| SCHEMBL24721442 | 0.89 | FNTA (0.31) | FNTAFNTBMAP3K14 | |
| SCHEMBL31169399 | 0.89 | FNTA (0.31) | FNTAFNTBMAP3K14NR1H2 | |
| SCHEMBL23576784 | 0.89 | FNTA (0.31) | FNTAFNTBMAP3K14 | |
| SCHEMBL23576786 | 0.89 | FNTA (0.31) | FNTAFNTBMAP3K14 | |
| SCHEMBL29909384 | 0.89 | FNTA (0.31) | FNTAFNTBMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | FNTA 968/4885FNTB 743/4885MAP3K14 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.